Compugen Ltd.
72 Pinchas Rosen Street
Tel Aviv
69512
Tel: 972-3-765-8585
Fax: 972-3-765-8555
Website: http://www.cgen.com/
Email: info@cgen.com
435 articles about Compugen Ltd.
-
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
3/11/2024
Compugen Ltd. announced that it has been selected to give two oral presentations at the Keystone Symposium on Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance, taking place March 17-21, 2024, in Whistler, Canada.
-
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
3/6/2024
Compugen Ltd. announced that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the American Association for Cancer Research annual meeting on April 5-11, 2024, in San Diego, California.
-
Compugen Reports Fourth Quarter and Full Year 2023 Results
3/5/2024
Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported financial results for the fourth quarter and full year 2023 and provided a corporate update.
-
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
2/26/2024
Compugen Ltd. today announced that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida, on Monday, March 11, 2024 at 11:20 AM ET.
-
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
2/15/2024
Compugen Ltd., a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024.
-
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
1/8/2024
Compugen Ltd. announced that Compugen is entitled to receive a $10 million milestone payment from AstraZeneca, after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.
-
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
12/19/2023
Compugen Ltd. today announced it will be eligible to receive a milestone payment of $10 million from AstraZeneca (LSE/STO/Nasdaq: AZN), when the first patient is dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.
-
Israel-based cancer immunotherapy company Compugen will receive $60 million upfront from Gilead for the license to its antibody, which blocks the interaction between the IL-18 binding protein and IL-18.
-
Executives from Israel-based companies express concern about future investment and other operational impacts, as the war rages on in Gaza with tragic loss of life amid political and economic uncertainties.
-
Compugen Reports Third Quarter 2023 Results
11/7/2023
Compugen Ltd. a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced financial results for the third quarter ended September 30, 2023, and provided a corporate update.
-
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
11/3/2023
Compugen Ltd. announced that on November 3, 2023, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq Listing Rule 5550.
-
Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023
10/24/2023
Compugen Ltd. announced, that the Company will release its third quarter 2023 financial results on Tuesday, November 7, 2023, before the U.S. financial markets open.
-
Compugen to Present at Single Cell Genomics 2023 Meeting
10/3/2023
Compugen Ltd. today announced, it will present innovative single-cell approaches and high resolution single cell spatial transcriptomics data at the Single Cell Genomics 2023 meeting taking place between 9-11 October 2023, Engelberg, Switzerland.
-
Compugen Reports Second Quarter 2023 Results
8/7/2023
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on key events since the start of 2023.
-
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023
7/24/2023
Compugen Ltd. today announced that the Company will release its second quarter financial results on Monday, August 7, 2023, before the U.S. financial markets open.
-
Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study
6/22/2023
Compugen Ltd. today announced that the first patient has been dosed in the triple immunotherapy combination proof-of-concept study evaluating COM701, Compugen's potential first-in-class anti-PVRIG antibody, with COM902, Compugen's potential best-in-class anti-TIGIT antibody and pembrolizumab in patients with platinum resistant ovarian cancer.
-
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement
6/13/2023
Compugen Ltd. announced that on June 12, 2023, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550.
-
Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer
6/5/2023
Compugen Ltd. today announced data to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, showing that Compugen's COM701 (anti-PVRIG) in triple combination with nivolumab and BMS-986207 (anti-TIGIT) demonstrated preliminary signal of durable anti-tumor activity in patients with recurrent, metastatic MSS endometrial cancer with a favorable safety profile.
-
Compugen Reports First Quarter 2023 Results
5/15/2023
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update on key events since the start of 2023.
-
Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023
5/11/2023
Compugen Ltd. today announced that the Company will host a virtual DNAM-1 Axis Investor Event on Tuesday, May 23, 2023 at 12:00 pm ET.